Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-C93 first-line pembrolizumab versus platinum doublet chemotherapy in dMMR advanced or recurrent endometrial carcinoma
NL-OMON53504Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on NL-OMON53504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53504.